Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal
We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 29(2023), 3 vom: 05. März, Seite 569-575 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kislaya, Irina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.02.2023 Date Revised 21.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2903.221367 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352471247 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352471247 | ||
| 003 | DE-627 | ||
| 005 | 20231226053812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2903.221367 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352471247 | ||
| 035 | |a (NLM)36737101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kislaya, Irina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.02.2023 | ||
| 500 | |a Date Revised 21.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BA.2 | |
| 650 | 4 | |a BA.5 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a Portugal | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a death | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a postinfection vaccine effectiveness | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a vaccine-preventable diseases | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Casaca, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Borges, Vítor |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Bibiana I |e verfasserin |4 aut | |
| 700 | 1 | |a Fonte, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Eugénia |e verfasserin |4 aut | |
| 700 | 1 | |a Dias, Carlos Matias |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Sílvia |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, José Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Grenho, Inês |e verfasserin |4 aut | |
| 700 | 1 | |a Coelho, Luís |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, Patrícia Pita |e verfasserin |4 aut | |
| 700 | 1 | |a Borges, Cláudia Medeiros |e verfasserin |4 aut | |
| 700 | 1 | |a Isidro, Joana |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Menezes, Luís |e verfasserin |4 aut | |
| 700 | 1 | |a Sobral, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Gonçalves, António Maia |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira, Luís |e verfasserin |4 aut | |
| 700 | 1 | |a Gomes, João Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Leite, Pedro Pinto |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Baltazar |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Ausenda |e verfasserin |4 aut | |
| 700 | 1 | |a Peralta-Santos, André |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 29(2023), 3 vom: 05. März, Seite 569-575 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:3 |g day:05 |g month:03 |g pages:569-575 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2903.221367 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 3 |b 05 |c 03 |h 569-575 | ||